| Name | Title | Contact Details |
|---|
For 27 years and counting, SLAM has been the most authentic brand in basketball storytelling. What started as a magazine in 1994 has now grown into a global lifestyle brand and multimedia property with 20-plus social channels, a burgeoning merchandise division and multiple franchise events annually. With over 16 million engaged followers across the globe, SLAM and its channels reach fans of the NBA, WNBA, college and high school, and the worlds of fashion, sneakers, gaming and more in a unique and trusted voice. The cover of SLAM remains the Holy Grail for basketball players; if you want to play in the NBA or WNBA, you want to be on the cover of SLAM.
Welcome to The IN Group! The IN Group (TIG) beautifully brings together the magic of the group individual brands, Investigo, InX, Definia, Caraffi, Sigma Labs & BioTalent enabling us to design truly bespoke solutions. Our mission is simple - to unlock the power of people. We know that conventional recruitment cant always solve todays talent challenges, so we decided to break with convention and offer you SO much more with TIG. Meet our brands - Investigo – we recruit the talent you need - InX – we find the best leaders - Definia – we deliver digital programmes - Caraffi – we offer talent advisory & talent solutions (EVP/CVP/MSP/RPO) - Sigma Labs - we offer outstanding graduates amplified with exceptional training in the world of Tech - BioTalent - we offer life sciences recruitment with the means to nurture change-makers Unashamedly human talent solutions At the IN Group, were unashamedly human, were encourage to be our true self and we love what we do. We think youll feel this through the people you meet, the solutions we design and the results youll enjoy. We believe that when people rally behind an ambitious vision and a brilliant culture, it lights up every corner of your organisation. We believe in people, so they make change for better. Wed love to tell you more so come and say hello@wearetig.com and well tell you all about it!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The PWHL is first-of-its-kind womens hockey league that brings together the best players in the world. Our league is comprised of six teams in North America, including: PWHL Boston, PWHL Minnesota, PWHL Montréal, PWHL New York, PWHL Ottawa, and PWHL Toronto.